Metastatic Prostate Cancer Clinical Trial
Official title:
PROSPECTIVE EVALUATION OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC PROSTATE CANCER
The investigators aim to test the safety and feasibility of prostate gland stereotactic body radiotherapy (SBRT) plus best systemic therapy in newly diagnosed metastatic prostate cancer.
The investigators and other investigators have previously documented the safety and efficacy
of definitive intent stereotactic body radiotherapy (SBRT) in the treatment of localized
prostate cancer.
In the metastatic setting for multiple malignancies, improved survival rates and disease
outcomes have been shown with definitive treatment of the primary disease site. This concept
of "cytoreductive" surgery or decreasing the primary tumor burden is now considered the
standard of care for metastatic colon, ovarian, renal cell, and some breast carcinomas (plus
post-surgery irradiation).
With new guidelines and declining rates of PSA screening, the incidence of newly diagnosed
metastatic prostate cancer is expected to increase. A recent population-based study has
concluded significant improvements in the definitive treatment of the local prostate cancer
in the stage IV setting with either radical prostatectomy or conventional prostate radiation
treatments/brachytherapy. To our knowledge, one prospective phase II trial is currently
accruing patients to best systemic therapy or best systemic therapy (BST) plus definitive
treatment with either radical prostatectomy or conventionally fractionated radiation therapy
The investigators hypothesize that the addition of primary disease SBRT to best systemic
therapy for newly diagnosed metastatic prostate cancer would be associated with an acceptable
safety profile, quality of life, disease progression, and overall survival. The addition of
SBRT to best systemic therapy is also expected to be better-received for stage IV patients
(with relatively limited prognosis), vs. fully fractionated radiation therapy, brachytherapy,
or radical prostatectomy. The above endpoints would initially be tested in a prospective
phase II multi-institutional trial and in comparison with historical controls.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
| Recruiting |
NCT04533958 -
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy
|
N/A | |
| Not yet recruiting |
NCT06009549 -
A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
|
||
| Withdrawn |
NCT05771896 -
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
|
Phase 3 | |
| Completed |
NCT01981122 -
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01233557 -
Biomarkers of Bone Resorption in Metastatic Prostate Cancer
|
N/A | |
| Completed |
NCT01012141 -
Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT04067713 -
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
|
||
| Active, not recruiting |
NCT04332744 -
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
|
Phase 2 | |
| Completed |
NCT04545697 -
mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer
|
N/A | |
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04031378 -
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
|
Phase 2 | |
| Completed |
NCT02278055 -
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT04193657 -
Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
|
||
| Completed |
NCT02260817 -
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
|
Phase 3 | |
| Terminated |
NCT00216060 -
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
|
Phase 3 | |
| Recruiting |
NCT04070209 -
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
|
Phase 2 | |
| Recruiting |
NCT04925648 -
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
|
Phase 2 | |
| Completed |
NCT01303705 -
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
|
Phase 1 |